Kazia Therapeutics Ltd ADR (KZIA : NASDAQ)
Common Stock
$10.20
USD
+0.00 (%)
Last updated: 2026-09-17
Get KZIA alerts:
KZIA
Kazia Therapeutics Ltd ADR
WealthAwesomePerformance
1 Day
-1.54%
1 Week
-14.14%
1 Month
-24.78%
YTD
-28.42%
Key Statistics
Market Cap
$116.55M
52W High
$17.40
52W Low
$4.86
P/E Ratio
-
50 Day MA
$12.97
200 Day MA
$10.62
Beta
2.15
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/17/2026 | $10.52 | $10.90 | $10.16 | $10.86 | $10.86 | 446,800 |
| 9/16/2026 | $10.50 | $10.97 | $10.15 | $10.20 | $10.20 | 353,800 |
| 9/15/2026 | $11.11 | $11.11 | $10.21 | $10.36 | $10.36 | 495,700 |
| 9/14/2026 | $11.12 | $11.64 | $11.12 | $11.16 | $11.16 | 153,200 |
| 9/11/2026 | $11.10 | $11.43 | $10.83 | $11.19 | $11.19 | 340,700 |
| 9/10/2026 | $11.75 | $11.75 | $10.83 | $11.01 | $11.01 | 374,300 |
| 9/9/2026 | $12.50 | $12.75 | $11.76 | $11.88 | $11.88 | 238,000 |
| 9/8/2026 | $12.29 | $12.47 | $11.95 | $12.01 | $12.01 | 158,700 |
| 9/4/2026 | $12.00 | $12.62 | $11.77 | $12.31 | $12.31 | 414,400 |
| 9/3/2026 | $12.62 | $12.99 | $12.04 | $12.16 | $12.16 | 413,500 |
Analyst Price Targets
Based on 1 analyst covering KZIA · as of Sep 17, 2026
Wall Street analysts forecast KZIA stock price to rise 181.6% over the next 12 months.
Consensus
Buy4.00 / 5.00
Avg. Target
US$28.73
+181.6% Upside
Current Price
US$10.20
Last close
Analyst Breakdown (1 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on KZIA's historical volatility
30-Day Vol
105.6%
Annualized
90-Day Vol
84.0%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$9.08
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$10.23 | US$7.11 – US$14.73 |
| 60 trading days | US$9.64 | US$5.76 – US$16.14 |
| 90 trading days | US$9.08 | US$4.83 – US$17.07 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Kazia Therapeutics Ltd ADR
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Financials
- Revenue (TTM)
- $1.90M
- EBITDA
- $-17.84M
- Profit Margin
- 0.00%
- ROE (TTM)
- -106.90%
- EPS (Diluted)
- -7.47
- Book Value
- 2.92
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About KZIA.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| DLXY | Delixy Holdings Limited Ordinary Shares | $2.29 | +451.81% |
| MEDS | DataMEDS AI, Inc. | $6.07 | +274.69% |
| SNYR | Synergy CHC Corp. Common Stock | $0.27 | +234.15% |
| QCLS | Q/C Technologies, Inc. | $0.96 | +118.45% |
| AEHL | Antelope Enterprise Holdings Ltd | $9.22 | +78.68% |
| ZTG | Zenta Group Company Limited | $1.18 | +75.33% |
| PDSB | PDS Biotechnology Corp | $0.99 | +69.25% |
| TPST | Tempest Therapeutics Inc | $1.21 | +60.18% |